We offer scalable cGMP solutions for
life science companies seeking to secure and grow their biomanufacturing capacity.
Accelerating Speed to Market Through High-Performance Shell
GeneSuites is introducing a new cGMP manufacturing solution to remove barriers for life science companies ready to manufacture life-changing therapies.
Through its High-Performance Shell (“HPS”), GeneSuites makes possible the availability of biomanufacturing capacity with greater user certainty, accelerating speed to market improvements by 18 months or greater, and increasing capital efficiencies while maximizing control over intellectual property and manufacturing process.
The GeneSuites Advantage
Expert
cGMP Team
Combining cGMP, financing, and real estate expertise to develop solutions that remove existing barriers for biomanufacturing
Accelerate
Speed to Market
Unprecedented approach to building flexible cGMP facilities that can easily adapt to new modalities and processes
Maximize
Quality Control
Through a hybrid approach, maintain total control of manufacturing process and environment
Secure
Intellectual Property
Maximize control of intellectual property, process, methodologies, and tech transfers
Maintain
Flexibility
Ability to accommodate multiple therapies, processes and technologies within the same facility
Leverage
Scalability
Can accommodate pre-clinical through commercial scale
Expanding Across Major Life Science Markets
GeneSuites has entered the Raleigh-Durham market with Catalyst BioCampus and will continue to expand across major life science markets in the United States and abroad.
Over 300,000 SF of purpose-built cGMP space at Catalyst is under construction and is on track to be operational by Q4 2023.
High-Performance Shell:
First of its Kind in North Carolina
Purpose-built cGMP Biomanufacturing Campus
In partnership with affiliates of Apollo Global Management, GeneSuites is developing Catalyst BioCampus, a three-building cGMP biomanufacturing campus located in Raleigh-Durham, NC.
Catalyst BioCampus is designed to accelerate critical manufacturing capacity for cell & gene therapy, monoclonal antibody – as well as other modalities – by 9-15 months.
